Skip to content
10-Q

Quarterly Report

Zyla Life Sciences

0001558370-19-008066

← back to feed
Filed
Aug 13, 2019 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2019 · Aug 9, 2019 9.36M sh
Capex Q2 2019 · Jun 30, 2019 $24K
Operating Cash Flow Q2 2019 · Jun 30, 2019 −$13.78M
Long Term Debt Q2 2019 · Jun 30, 2019 $97.2M
Short Term Debt Q2 2019 · Jun 30, 2019 $4.43M
Short Term Debt Q2 2019 · Jan 31, 2019 $1.49M
Cash And Equivalents Q2 2019 · Jun 30, 2019 $12.05M
Cash And Equivalents Q2 2019 · Jan 31, 2019 $17.05M
Stockholders Equity Q2 2019 · Jun 30, 2019 $57.68M
Stockholders Equity Q2 2019 · Mar 31, 2019 $76.51M
Stockholders Equity Q2 2019 · Jan 31, 2019 $86.94M
Current Liabilities Q2 2019 · Jun 30, 2019 $64.54M
Current Liabilities Q2 2019 · Jan 31, 2019 $58.86M
Current Assets Q2 2019 · Jun 30, 2019 $50.2M
Current Assets Q2 2019 · Jan 31, 2019 $64.1M
Total Assets Q2 2019 · Jun 30, 2019 $235.57M
Total Assets Q2 2019 · Jan 31, 2019 $254.15M
Sga Expense Q2 2019 · Jun 30, 2019 $7.42M
Sga Expense Q2 2019 · Jun 30, 2019 $10.78M
Rd Expense Q2 2019 · Jun 30, 2019 $4K
Rd Expense Q2 2019 · Jun 30, 2019 $11K
Net Income Q2 2019 · Jun 30, 2019 −$30.13M
Operating Income Q2 2019 · Jun 30, 2019 −$15.54M
Operating Income Q2 2019 · Jun 30, 2019 −$23.22M
Revenue Q2 2019 · Jun 30, 2019 $22.03M
Revenue Q2 2019 · Jun 30, 2019 $37.84M